KALARIS THERAPEUTICS, INC. Segment Reporting Other Item Amount
KALARIS THERAPEUTICS, INC. (KLRS) reported Segment Reporting Other Item Amount of -$871.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. segment reporting other item amount for the quarter ending 2026-06-30 was -$871.00K.
- KALARIS THERAPEUTICS, INC. segment reporting other item amount for the quarter ending 2026-03-31 was -$977.00K.
- KALARIS THERAPEUTICS, INC. segment reporting other item amount for the quarter ending 2025-12-31 was -$803.00K, a 105.91% decline year-over-year.
- KALARIS THERAPEUTICS, INC. segment reporting other item amount for the quarter ending 2025-09-30 was -$847.00K.
- KALARIS THERAPEUTICS, INC. segment reporting other item amount for fiscal 2025 was -$4.16M, a 128.21% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. segment reporting other item amount for fiscal 2024 was $14.73M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$871.00K 10-Q · filed 2026-08-11 | -$1.85M 10-Q · filed 2026-08-11 | -$2.65M derived: sum of 3 quarters · filed 2026-08-11 | -$3.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$977.00K 10-Q · filed 2026-05-12 | -$1.78M derived: sum of 2 quarters · filed 2026-05-12 | -$2.63M derived: sum of 3 quarters · filed 2026-05-12 | -$3.53M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$1.65M derived: sum of 2 quarters · filed 2026-03-17 | -$2.56M derived: sum of 3 quarters · filed 2026-08-11 | -$4.16M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$847.00K 10-Q · filed 2025-11-12 | -$1.75M derived: sum of 2 quarters · filed 2026-08-11 | -$3.35M 10-Q · filed 2025-11-12 | $10.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$906.00K 10-Q · filed 2026-08-11 | -$2.51M 10-Q · filed 2026-08-11 | $11.08M derived: sum of 3 quarters · filed 2026-08-11 | $10.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.60M 10-Q · filed 2026-05-12 | $11.98M derived: sum of 2 quarters · filed 2026-05-12 | $11.40M derived: sum of 3 quarters · filed 2026-05-12 | $12.37M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $13.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $13.00M derived: sum of 2 quarters · filed 2026-03-17 | $13.97M derived: sum of 3 quarters · filed 2026-03-17 | $14.73M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$580.00K 10-Q · filed 2025-11-12 | $384.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.15M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $964.00K 10-Q · filed 2025-08-13 | $1.73M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $766.00K 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |